Natalizumab (Tysabri) Order Form

PATIENT & PRESCRIBER INFORMATION				
Patient Name:	DOB:	Phone: (H	(C)	
Patient Address:				
Ht.: Wt.: 🗆 lbs. 🗆 kg. Allergie	es:			
Prescriber Name/Title: Address: Address:				
Phone: Fax:	Prescriber NPI #:			
REQUIRED: Most Recent H&P, clinical notes, & medication list are required unless the patient is established with SOMC. Supporting clinical notes should include any past tried and/or failed therapies, intolerance, outcomes, or contraindications to conventional therapy. LAB RESULTS: Include Negative TB and Hepatitis B tests.				
DIAGNOSIS, CLINICAL INFORMATION, & PRESCRIPTION				
Infusion rates will follow manufacturer recommendations.				
 0.9% NaCl 250 ml primary at KVO during infusion, and flush line during observation period. In the event of an adverse reaction, line maintenance/flushes, or O2 are required, the SOMC AIC established protocols will be utilized. 				
 Monitor for any adverse events post administration for Pre-Treatment Medications: (Check all that apply) Tate Acetaminophen (Tylenol) 650 mg by mouth x 1 do 25 mg / □ 50 mg Diphenhydramine (Benadryl) □ Methylprednisolone (Solumedrol) 100 mg IVP x 1 de Other (Please Specify)	for at least 1 hour o be administere se PO or IV x 1 d dose IV x 1 d dose	for first 12 infus ad 30 minutes pr lose Sclerosis	ions or until clinically stable. ior to each administration. Multiple Sclerosis	n's Disease
☑ Natalizumab (Tysabri) 300 mg/15 mL in 100 mL NS over 1 hour every 4 weeks x 1 year.				
Additional order(s) Lab order(s) CBC I at each dose or every CBC w/ Diff at each dose or every CMP at each dose or every Other –				
PROVIDER:	DATE:	TIME:	SIGNATURE:	

Southern Ohio Medical Center